Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

7.4K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
7.4K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

4.8K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
4.8K
Disorders of Leukocytes01:27

Disorders of Leukocytes

1.2K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.2K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

4.0K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
4.0K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

1.6K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

International Trends in Head and Neck Cancer Mortality.

JAMA otolaryngology-- head & neck surgery·2026
Same author

Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System Involvement.

Blood advances·2026
Same author

Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma.

Blood cancer journal·2026
Same author

Autologous stem cell transplantation for AL amyloidosis: a multicenter summary of outcomes 2010-2020.

Bone marrow transplantation·2026
Same author

Prevalence and Burden of Cardiac Amyloidosis in a Population-Based Autopsy Cohort.

Circulation·2026
Same author

Incidence and treatment-modifying impact of immune checkpoint inhibitor-associated peripheral edema: a systematic review and meta-analysis.

JNCI cancer spectrum·2026
Same journal

Integrated Glycoproteomics Identifies Dynamic IgA1 N-Glycosylation and FUT8 as a Functional Mediator in Multiple Myeloma.

Hematological oncology·2026
Same journal

Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T-Cell Infusion: A Case Report With Mechanistic Insight.

Hematological oncology·2026
Same journal

Efficacy and Safety of Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.

Hematological oncology·2026
Same journal

Extracorporeal Cytokine Hemadsorption for the Treatment of Severe Steroid Refractory Cytokine Release Syndrome Secondary to T-Cell Immunotherapy for B-Cell Malignancies: A Case Series.

Hematological oncology·2026
Same journal

Glofitamab Induces Complete Responses in Relapsed and Refractory Primary Central Nervous System Lymphoma.

Hematological oncology·2026
Same journal

Impact of U2AF1 Pathogenic Variants on Prognosis of Myelodysplastic Neoplasms With RUNX1 Mutation.

Hematological oncology·2026
See all related articles

Related Experiment Video

Updated: Sep 19, 2025

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
12:58

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Published on: May 10, 2017

9.4K

Non-Clonal Lymphoproliferative Diseases.

Stefan Dirnhofer1, Yoshito Nishimura2, Angela Dispenzieri2,3

  • 1Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.

Hematological Oncology
|June 15, 2025
PubMed
Summary
This summary is machine-generated.

Castleman disease classification is improving, aiding understanding of pathology and treatment. Therapies vary by subtype, from surgery for unicentric to targeted treatments for multicentric forms.

Keywords:
Castleman disease (CD)HHV8IgG4‐related diseaselymphoma

More Related Videos

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines
06:38

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

40.6K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.3K

Related Experiment Videos

Last Updated: Sep 19, 2025

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
12:58

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Published on: May 10, 2017

9.4K
Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines
06:38

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

40.6K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.3K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Castleman disease encompasses a poorly understood spectrum of disorders.
  • Recent advancements, particularly from the Castleman's Disease Collaborative Network, are enhancing classification and understanding.
  • Accurate classification is crucial for comprehending underlying pathology and optimizing patient care.

Purpose of the Study:

  • To outline the current understanding and classification of Castleman disease.
  • To highlight the importance of recognizing and correctly categorizing Castleman disease based on established criteria.
  • To review emerging therapeutic strategies for different Castleman disease subtypes.

Main Methods:

  • Classification by anatomic spread (unicentric, oligocentric, multicentric).
  • Histopathological analysis (hypervascular to plasmacytic spectrum).
  • Clinical phenotype assessment (NOS, TAFRO, IPL, HHV8-associated, POEMS-associated).

Main Results:

  • Castleman disease requires classification by anatomy, histopathology, and clinical phenotype.
  • Therapeutic approaches are evolving, moving beyond retrospective data.
  • Unicentric disease is primarily treated with surgery.

Conclusions:

  • Multicentric Castleman disease treatment is subtype-specific.
  • Interleukin-6 blockade is key for non-POEMS, non-HHV8 multicentric cases.
  • HHV8-associated cases may involve rituximab, while POEMS subtypes require IL-6 blockade or plasma cell-directed therapy.